Search Results

Filter
  • 1-10 of  20 results for ""Liver-Specific Organic Anion Transporter 1""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Cooperative inhibitory effects of uremic toxins and other serum components on OATP1B1-mediated transport of SN-38.

  • Authors : Katsube Y; Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Kyoto Pharmaceutical University, 5 Misasagi Nakauchi-cho, Yamashina-ku, Kyoto, 607-8414, Japan.; Tsujimoto M

Subjects: Antineoplastic Agents, Phytogenic/Antineoplastic Agents, Phytogenic/Antineoplastic Agents, Phytogenic/*metabolism ; Camptothecin/Camptothecin/Camptothecin/*analogs & derivatives ; Liver-Specific Organic Anion Transporter 1/Liver-Specific Organic Anion Transporter 1/Liver-Specific Organic Anion Transporter 1/*metabolism

  • Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2017 Apr; Vol. 79 (4), pp. 783-789. Date of Electronic Publication: 2017 Mar 17.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms.

  • Authors : Nozawa T; Department of Molecular Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamasaki, Noda, Chiba 278-8510, Japan.; Minami H

Subjects: Polymorphism, Single Nucleotide*; Camptothecin/Camptothecin/Camptothecin/*analogs & derivatives ; Liver-Specific Organic Anion Transporter 1/Liver-Specific Organic Anion Transporter 1/Liver-Specific Organic Anion Transporter 1/*genetics

  • Source: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2005 Mar; Vol. 33 (3), pp. 434-9. Date of Electronic Publication: 2004 Dec 17.Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model:

Record details

×
Academic Journal

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.

  • Authors : de With M; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.; Department of Clinical Chemistry, Erasmus Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.

Subjects: Camptothecin*/Camptothecin*/Camptothecin*/adverse effects ; Antineoplastic Agents, Phytogenic*/Antineoplastic Agents, Phytogenic*/Antineoplastic Agents, Phytogenic*/adverse effects; Humans

  • Source: Clinical pharmacokinetics [Clin Pharmacokinet] 2023 Nov; Vol. 62 (11), pp. 1589-1597. Date of Electronic Publication: 2023 Sep 16.Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1926

Record details

×
Academic Journal

Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys.

  • Authors : Nagai Y; a Daiichi Sankyo Co., Ltd., Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd. Tokyo , Japan.; Oitate M

Subjects: Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/*pharmacokinetics ; Camptothecin/Camptothecin/Camptothecin/*analogs & derivatives ; Immunoconjugates/Immunoconjugates/Immunoconjugates/*pharmacokinetics

  • Source: Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2019 Sep; Vol. 49 (9), pp. 1086-1096. Date of Electronic Publication: 2019 Jan 04.Publisher: Informa Healthcare Country of Publication: England NLM ID: 1306665 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotecan Induced Side Effects.

  • Authors : Toshimoto K; Sugiyama Laboratory, RIKEN Innovation Center, RIKEN, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan.; Tomaru A

Subjects: Models, Biological* ; Polymorphism, Genetic*; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*adverse effects

  • Source: Pharmaceutical research [Pharm Res] 2017 Aug; Vol. 34 (8), pp. 1584-1600. Date of Electronic Publication: 2017 Apr 10.Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 8406521 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.

  • Authors : Teft WA; Department of Medicine, Division of Clinical Pharmacology, London Health Sciences Centre-University Hospital, Western University, Room B9-132, 339 Windermere Road, London, Ontario, Canada N6A 5A5.; Welch S

Subjects: Antineoplastic Agents, Phytogenic/Antineoplastic Agents, Phytogenic/Antineoplastic Agents, Phytogenic/*pharmacokinetics ; Camptothecin/Camptothecin/Camptothecin/*analogs & derivatives ; Colorectal Neoplasms/Colorectal Neoplasms/Colorectal Neoplasms/*drug therapy

  • Source: British journal of cancer [Br J Cancer] 2015 Mar 03; Vol. 112 (5), pp. 857-65. Date of Electronic Publication: 2015 Jan 22.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

Record details

×
Academic Journal

OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice.

  • Authors : Iusuf D; Corresponding Author: Alfred H. Schinkel, Division of Molecular Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. .; Ludwig M

Subjects: Camptothecin/Camptothecin/Camptothecin/*analogs & derivatives ; Carboxylic Ester Hydrolases/Carboxylic Ester Hydrolases/Carboxylic Ester Hydrolases/*genetics ; Organic Anion Transporters, Sodium-Independent/Organic Anion Transporters, Sodium-Independent/Organic Anion Transporters, Sodium-Independent/*genetics

  • Source: Molecular cancer therapeutics [Mol Cancer Ther] 2014 Feb; Vol. 13 (2), pp. 492-503. Date of Electronic Publication: 2013 Nov 05.Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited

Record details

×
Academic Journal

SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer.

  • Authors : Huang L; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.; Zhang T

Subjects: Polymorphism, Single Nucleotide*; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacology ; Camptothecin/Camptothecin/Camptothecin/*analogs & derivatives

  • Source: PloS one [PLoS One] 2013 Oct 15; Vol. 8 (10), pp. e77223. Date of Electronic Publication: 2013 Oct 15 (Print Publication: 2013).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

Record details

×
Academic Journal

Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.

  • Authors : De Mattia E; aExperimental and Clinical Pharmacology Unit bEpidemiology and Biostatistics Unit cMedical Oncology Unit, 'Centro di Riferimento Oncologico' - National Cancer Institute, Aviano dMedical Oncology Unit, 'San Filippo Neri Hospital', Rome eMedical Oncology Unit 1, Istituto Oncologico Veneto - IRCCS, Padova, Italy.; Toffoli G

Subjects: ATP-Binding Cassette Transporters/ATP-Binding Cassette Transporters/ATP-Binding Cassette Transporters/*genetics ; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Camptothecin/Camptothecin/Camptothecin/*analogs & derivatives IFL protocol

  • Source: Pharmacogenetics and genomics [Pharmacogenet Genomics] 2013 Oct; Vol. 23 (10), pp. 549-57.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 101231005 Publication Model: Print Cited Medium: Internet

Record details

×
Academic Journal

The effect of breast cancer resistance protein, multidrug resistant protein 1, and organic anion-transporting polypeptide 1B3 on the antitumor efficacy of the lipophilic camptothecin 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in vitro.

  • Authors : Tsakalozou E; Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA.; Adane ED

Subjects: ATP Binding Cassette Transporter, Subfamily B, Member 1/ATP Binding Cassette Transporter, Subfamily B, Member 1/ATP Binding Cassette Transporter, Subfamily B, Member 1/*physiology ; ATP-Binding Cassette Transporters/ATP-Binding Cassette Transporters/ATP-Binding Cassette Transporters/*physiology ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacology

  • Source: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2013 Jul; Vol. 41 (7), pp. 1404-13. Date of Electronic Publication: 2013 Apr 25.Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model:

Record details

×
  • 1-10 of  20 results for ""Liver-Specific Organic Anion Transporter 1""